_edited.png)
How to adapt cosmetics CPSR from the EU and the UK to the USA
- Daniel Jiménez
- 4 hours ago
- 4 min read
Many cosmetic brands expanding into the United States already have a Cosmetic Product Safety Report (CPSR) prepared for the European Union or the United Kingdom. A common question is whether this documentation can be reused for the U.S. market — and if so, how.
While EU and UK safety assessments provide a strong scientific foundation, regulatory frameworks differ significantly between jurisdictions. Successfully entering the U.S. market requires more than simply translating or reformatting an existing CPSR.
This article explains the key differences and what companies should consider when adapting EU or UK safety documentation for the United States.
Table of Contents
Do Cosmetics Require a CPSR in the United States?
Unlike the EU and UK, the United States does not legally require a formal CPSR document with the same structure defined under Regulation (EC) No. 1223/2009.
However, U.S. law requires that cosmetic products be safe for their intended use, and companies must maintain adequate safety substantiation to support that conclusion.
Under the Modernization of Cosmetics Regulation Act (MoCRA), companies responsible for marketing cosmetics in the U.S. must ensure they possess:
Safety data supporting product use
Evidence demonstrating safe formulation
Documentation supporting ingredient safety
Records available for FDA inspection if requested
Therefore, while the format differs, scientific expectation remains comparable.
Key Differences Between EU/UK CPSR and U.S. Requirements
Several regulatory differences must be considered when adapting documentation.
1. Regulatory Framework
EU and UK cosmetics operate under detailed regulatory frameworks requiring:
CPSR Parts A and B
Qualified safety assessor sign-off
Responsible Person obligations
Product Information File (PIF)
The U.S. system focuses more on substantiation of safety rather than prescribed documentation formats.
This difference often creates confusion when companies attempt to reuse EU documentation directly.
2. Ingredient Regulatory Landscape
Ingredient restrictions differ between jurisdictions.
Examples include:
Color additives approval requirements in the U.S.
Different prohibited and restricted ingredient lists
Varying preservative and UV filter regulatory status
Fragrance allergen disclosure expectations (evolving under MoCRA)
Even when a formulation is compliant in the EU, additional evaluation may be required for the U.S.
3. Exposure and Risk Assessment Assumptions
Risk assessment methodologies are similar globally, but exposure assumptions may differ due to:
Consumer usage patterns
Product positioning and claims
Concentration limits under U.S. regulatory expectations
Population considerations
A direct transfer of exposure calculations may not always be appropriate.
4. Claims and Product Classification Risks
One of the most critical differences between EU/UK and U.S. regulatory environments involves claims.
In the United States, cosmetic claims that imply therapeutic or physiological effects may cause a product to be classified as a drug.
This risk is higher than in EU/UK markets and must be evaluated carefully when adapting documentation.
5. Labeling Requirements and Safety Warnings
Safety substantiation must align with U.S. labeling requirements.
Differences may include:
Mandatory warning statements
Product identity positioning
Ingredient declaration formatting
Regulatory terminology differences
Safety documentation and labeling must be consistent.
Can an EU&UK CPSR Be Used as a Starting Point?
Yes. An EU or UK CPSR can provide valuable scientific information, including:
Toxicological profiles
Ingredient safety data
Exposure assessments
Stability and microbiological data
Manufacturing information
However, adaptation is usually required to ensure alignment with U.S. regulatory expectations.
The extent of adaptation depends on:
Product category
Ingredients used
Claims strategy
Target consumer group
Manufacturing location
The Impact of MoCRA on Safety Documentation
MoCRA introduced new regulatory expectations that influence safety substantiation requirements.
Companies must now maintain documentation demonstrating that cosmetic products have been adequately evaluated for safety.
Additionally, FDA now has expanded authority to request access to certain safety records under specific circumstances.
This increases the importance of structured documentation aligned with U.S. expectations.
Additional Considerations for International Brands
Companies adapting EU or UK safety documentation should also consider:
Facility registration requirements
Cosmetic product listing obligations
Responsible Person roles under MoCRA
Adverse event reporting systems
Importation and supply chain structure
Safety documentation is only one component of overall compliance.
Common Challenges When Adapting CPSRs
Across international projects, several recurring challenges appear:
Assuming EU compliance equals U.S. compliance
Overlooking color additive regulations
Claims creating unintended drug classification
Inconsistent labeling and safety documentation
Missing alignment with MoCRA requirements
Lack of clarity regarding regulatory responsibility
These issues can delay market entry or create compliance risks.
Strategic Approach to U.S. Safety Substantiation
Companies entering the U.S. market benefit from a structured regulatory strategy that considers:
Ingredient regulatory status evaluation
Claims positioning assessment
Exposure and toxicological review
Labeling alignment
MoCRA compliance requirements
Documentation readiness for FDA inspection
A proactive approach reduces regulatory uncertainty.
Why Regulatory Expertise Is Often Needed
Although EU CPSRs provide strong scientific foundations, adapting them to the U.S. market involves regulatory interpretation rather than simple conversion.
Companies must align scientific data with U.S. legal frameworks, market positioning, and evolving regulatory expectations.
This combination of scientific and regulatory considerations often requires specialized expertise.
EU and UK CPSRs can serve as valuable starting points for U.S. cosmetic safety substantiation, but they cannot usually be transferred without modification.
Understanding regulatory differences, ingredient requirements, claims risks, and MoCRA obligations is essential for successful adaptation.
Companies planning to enter the U.S. cosmetic market should evaluate safety documentation early to ensure efficient compliance and market access.
If your company already has EU or UK cosmetic safety documentation and is planning to enter the United States market, Belab Services can support you.
Our regulatory specialists assist international brands with:
Adaptation of EU/UK CPSR documentation for the U.S.
Cosmetic safety substantiation strategy
MoCRA compliance support
Labeling and claims review
Facility registration and product listing
U.S. market entry planning
Comments